OutPerformDaily

  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks

Lost Password?
Amazon vs. Costco: Which Stock Is a Better Buy?

Amazon vs. Costco: Which Stock Is a Better Buy?

Cross Staff Loads Up on 289,000 Shares of AKRE

Cross Staff Loads Up on 289,000 Shares of AKRE

Prediction: This Artificial Intelligence (AI) Stock Will Join Nvidia, Apple, and Alphabet in the $3 Trillion Club Before 2028

The billion-dollar infrastructure deals powering the AI boom

AI Boom May Be Creating Hidden Risks In Housing Market

Cisco’s Secure AI Factory Links Sovereign Data Push To Valuation Story

OutPerformDaily
  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks
OutPerformDaily
  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks
Earnings live: Supermicro, Eli Lilly stocks pop on upbeat forecasts, AMD and Uber slide
Uncategorized

Earnings live: Supermicro, Eli Lilly stocks pop on upbeat forecasts, AMD and Uber slide

February 4, 2026

More Big Tech earnings are ahead from Amazon and Alphabet.

3rdPartyFeeds

Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better

February 4, 2026

Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday...

Tesla’s China-made EV sales rise 9.3% y/y in January
Uncategorized

Tesla’s China-made EV sales rise 9.3% y/y in January

February 4, 2026

BEIJING, Feb 4 () – Tesla sold 69,129 ​China-made electric vehicles ‌in January, up 9.3% ‌from a year earlier, extending gains for a third ⁠consecutive...

Waymo crosses major threshold amid nagging issues
Uncategorized

Waymo crosses major threshold amid nagging issues

February 3, 2026

A private company valued at $1 billion or more used to be so rare that venture capitalists began referring to such firms as “unicorns,” connoting...

Eli Lilly Is Getting Into the Hearing Loss Market in a $1.12 Billion Deal With Seamless Therapeutics
Uncategorized

Eli Lilly Is Getting Into the Hearing Loss Market in a $1.12 Billion Deal With Seamless Therapeutics

February 3, 2026

While riding high on the popularity of its weight loss drug Zepbound, the company is quietly building a presence in a cutting-edge healthcare segment.

3rdPartyFeeds

Why PayPal Stock Crashed Today

February 3, 2026

CEO Alex Chriss is stepping down. Read More...

3rdPartyFeeds

3 Reasons to Buy the Dip on Microsoft Stock

February 3, 2026

Microsoft's recent 10% sell-off offers a great potential stock-buying opportunity. Read More...

3rdPartyFeeds

AMD shares drop as forecast comes up short of some expectations

February 3, 2026

AMD's first-quarter forecast fell short of what some analysts were hoping for amid an AI spending boom. Read more...

3rdPartyFeeds

AMD shares drop as forecast comes short of some expectations

February 3, 2026

AMD's first-quarter forecast fell short of what some analysts were hoping for amid an AI spending boom. Read more...

3rdPartyFeeds

Chipotle stock sinks as restaurant chain reports falling traffic, weak guidance

February 3, 2026

Chipotle stock has fallen about 33% over the last year, dragging the company's market value down to about $51 billion. Read more...

Previous 1 … 30 31 32 33 34 … 8,454 Next
Indices by TradingView

Categories

  • 3rdPartyFeeds
  • Cannabis Stocks
  • Index Funds
  • International
  • News
  • Short
  • Stock Picks
  • Tech Stocks
  • Uncategorized
Indices by TradingView
While subscribers receive the benefit of Outperformdaily opinions, none of the information contained therein constitutes a recommendation from Outperformdaily that any particular security, portfolio of securities, transaction, option, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Outperformdaily may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Outperformdaily’s past results are not necessarily indicative of future performance. All investments are subject to loss. Our employees and writters typically personally invest in all recommendations, but they are not obligated too. Our employees and writters are prohibited from taking an opposite position from which they write about.